News & Deep Analysis
GILD

Gilead Q3 2025: Revenue +3%, EPS $2.43

Published: October 30, 2025
GILEAD SCIENCES, INC.

Direct News

  • Revenue increased 3% year-over-year in Q3 2025.
  • GAAP EPS rose to $2.43 in Q3 2025, roughly double the year-ago quarter.
  • HIV franchise and established product portfolio remain core revenue drivers.
  • On Oct. 6, 2025 Gilead announced a settlement extending Biktarvy patent exclusivity to 2036.

Historical Context

Gilead’s Q3 2025 results follow a year in which the company has leaned on its established HIV portfolio and pushed forward multiple development programs. Earlier in 2025, Q1 disclosures emphasized the HIV franchise’s central role (Biktarvy reported $3.15 billion in Q1 2025) and a geographic revenue split heavily weighted toward the U.S. (roughly 70% of product sales). On Oct. 6, 2025, Gilead announced a settlement that extends Biktarvy’s patent exclusivity to 2036, a material legal outcome that supports the company’s core HIV revenue outlook. The company has also dealt with program-level setbacks and portfolio write-downs in prior periods (for example, the Trodelvy NSCLC program was discontinued in September 2024), illustrating the uneven nature of biotech R&D outcomes even as legacy products continue to generate cash flow.

Q3 results in investor context

Gilead reported a modest 3% year-over-year revenue increase in the third quarter of 2025 while EPS rose to $2.43, roughly double the comparable quarter a year earlier. For investors, the combination of headline revenue growth and a sizable rise in earnings per share highlights improved profitability metrics even as top-line expansion remains single-digit. The results should be interpreted against Gilead’s portfolio mix: HIV single-tablet regimens and other established products continue to dominate sales. Prior-period and first-quarter 2025 disclosures show the HIV franchise as the company’s core revenue engine, and the Oct. 6, 2025 settlement extending Biktarvy exclusivity to 2036 reinforces the underlying revenue runway for that franchise.

Product mix and geographic exposure

Gilead’s product mix centers on HIV treatments (notably Biktarvy, Genvoya, Descovy), antiviral medicines (Epclusa, Veklury) and oncology assets (Yescarta, Tecartus, Trodelvy) alongside supportive products such as AmBisome. Earlier 2025 disclosures show Biktarvy as a major contributor to sales (Biktarvy reported $3.15 billion in Q1 2025), underscoring the regimen’s importance to quarterly performance. Geographically, the U.S. accounts for the majority of product sales — roughly 70% based on Q1 2025 reporting — with Europe and Rest of World representing smaller shares. That U.S.-weighted exposure makes Gilead sensitive to U.S. reimbursement dynamics and wholesaler/distributor channels that drive the majority of domestic flows.

Pipeline, patents and financial considerations

Gilead’s near-term growth strategy combines its commercial HIV franchise with development-stage assets. Pipeline priorities cited in company disclosures include lenacapavir (long-acting HIV PrEP candidate), CAR-T and cell therapies in oncology, and late-stage programs for HDV (bulevirtide) and ADCs (sacituzumab govitecan-hziy / Trodelvy) in various indications. The company’s balance sheet and intangible asset profile reflect material finite-lived intangibles and IPR&D, with noted amortization and impairment activity in 2025. These intangible assets and patent protections provide a partial moat, but investors should weigh finite patent lives, amortization/impairment charges and the potential for generic erosion over time.

Key risks for investors

Risks highlighted in company disclosures remain relevant after the Q3 release: ongoing product liability and litigation exposures, regulatory and clinical development uncertainty (including prior program discontinuations such as the Trodelvy NSCLC program), and reimbursement or pricing pressures in major markets. Currency translation and R&D impairment risk were also cited as potential headwinds in 2025. Given the concentration of sales in the U.S. and reliance on a handful of high-value therapies, investors should monitor upcoming regulatory milestones for pipeline assets, patent developments, and quarterly trends in product-level performance to assess sustainability of revenue and earnings growth.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at GILEAD SCIENCES, INC. as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

1

Create Your Free Account

Sign up or log in to access your personal dashboard.

2

Select Your Focus

Use the search bar to find companies like GILEAD SCIENCES, INC.. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

3

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"

More Strategic Insights

GILD
May 20, 2026

Gilead Issues $3B Senior Notes maturing 2028–2034

Read Analysis
GILD
Feb 23, 2026

GILD: FDA Accepts Arcellx Anito-cel BLA

Read Analysis
GILD
Feb 23, 2026

GILD: Board Restructuring Linked to Merger

Read Analysis
GILD
Feb 23, 2026

Gilead to Acquire Arcellx at $115 + CVRs

Read Analysis